RNA oncology company TransCode Therapeutics Inc (NASDAQ:RNAZ) announced on Thursday that the third patient in Cohort 4 of its Phase 1a clinical trial has received their initial dose of TTX-MC138.

All cohorts have enrolled at least three patients who have been dosed with TTX-MC138 at least once. The Safety Review Committee monitoring the clinical trial unanimously approved opening the fourth cohort based on its review of available safety and pharmacokinetic (PK) data.

Additionally, the Safety Review Committee approved expanded enrolment in Cohort 3 to obtain additional safety data. To date, 15 patients have received at least one dose of TTX-MC138 at four separate dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. Three patients have been treated in the expanded enrolment.

Transcode said that observed tolerability profile and the available PK/PD results thus far support advancement of the clinical trial to further evaluate safety and potential anti-tumour activity of TTX-MC138 in the planned dose expansion (Phase 1b) portion of the trial.